Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Sch 1 Update - ISIS Resources

15 Sep 2006 11:23

AIM15 September 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: Verona Pharma plc (previously Isis Resources plc) COMPANY ADDRESS: Adderbury Hill Barn, Milton Road, Adderbury, Oxon COMPANY POSTCODE: OX17 3HN COUNTRY OF INCORPORATION: United Kingdom COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: The company is involved in drug discovery focused on the discovery and development of new therapeutic drugs for thetreatment of allergic rhinitis (hay fever) and other chronic respiratory and inflammatory diseases. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which itseeks admission and the number and type to be held as treasury shares): 144,275,000 Ordinary Shares of £0.001 each CAPITAL TO BE RAISED ON ADMISSION: £2.043 million FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Professor Clive Peter Page, Non-Executive Chairman Professor Michael John Alfred Walker, Chief Executive Officer Claire Louise Poll, Executive Director Professor Trevor Mervyn Jones, Non-Executive Director Herbert Stuart Bottomley, Non-Executive Director PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Prior to Admission %Craig Burton* 19.9Pershing Keen Nominees Ltd** 18.5Williams de Broe 7.0Stuart Bottomley*** 7.0Josef El Raghy 6.0Fitel Nominees Ltd a/c CO57658 5.6Jamie Boyton 4.8William Fairweather 4.6Fitel Nominees Ltd a/c CO58142 4.2Mark Freeman 4.0Tolle Investments Pty Ltd 4.0 * Mr. Burton's interests are held through the CI Burton Family Trust A/C and CI Burton Super Fund A/C ** Pershing Keen Nominees Ltd holds an additional 3,000,000 ordinary shares on behalf o f Josef El Raghy, a director of the Company *** Mr. Bottomley's interests are held through The Bank of New York (Nominees) Limited After admission %Fidelity Euro Smaller Companies Fund 9.70Craig Burton* 8.66Pershing Keen Nominees Ltd** 6.42Williams de Broe 5.80Stuart Bottomley*** 4.16Clive Page 3.92Michael Walker 3.91David Saint 3.91Millenium Capital Partners 3.19* Mr. Burton's interests are held through the CI Burton Family Trust A/C and CI Burton Super Fund A /C ** Pershing Keen Nominees Ltd holds an additional 3,000,000 ordinary shares on behalf o f Josef El Raghy, a director of the Company *** Mr. Bottomley's interests are held through The Bank of New York (Nominees) Limited NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: None ANTICIPATED ACCOUNTING REFERENCE DATE: 31 December EXPECTED ADMISSION DATE: 19 September 2006 NAME AND ADDRESS OF NOMINATED ADVISER: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ NAME AND ADDRESS OF BROKER: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THISWILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ DATE OF NOTIFICATION:15 September 2006UPDATE Update This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Oct 201312:06 pmPRNPlacing of shares
30th Sep 20137:00 amPRNHalf-yearly Report
23rd Sep 20137:00 amPRNNotice of Results
10th Sep 20137:00 amPRNClinical data presented at ERS
5th Sep 20137:01 amPRNPresentations at ERS
5th Sep 20137:00 amPRNAppointment of Richard Bungay as CFO
29th Jul 201310:13 amPRNGrant of Options
25th Jul 20131:23 pmPRNDirector Shareholding
24th Jul 20135:58 pmPRNHolding(s) in Company
23rd Jul 201312:45 pmPRNDirector Shareholding
24th Jun 20137:00 amPRNFirst patient dosed in clinical trial for VRP700
3rd Jun 20134:46 pmPRNResult of AGM
21st May 20134:00 pmPRNATS Tuesday Presentation
20th May 20137:00 amPRNATS Sunday Poster Presentations
16th May 20137:00 amPRNPresentations at ATS Conference
9th May 20138:05 amPRNPosting of Annual Report and AGM Notice
29th Apr 20137:00 amPRNNew Clinical and Scientific Advisory Board Announced
26th Apr 201310:17 amPRNDirector/PDMR Shareholding
15th Apr 20133:01 pmPRNGrant of Options
10th Apr 20133:07 pmPRNDirector's Dealing
10th Apr 201310:23 amPRNDirector Dealings
10th Apr 20137:00 amPRNFinal Results
19th Mar 20131:56 pmPRNHolding(s) in Company
5th Mar 20137:00 amPRNRPL554 demonstrates airway anti-inflammatory activity
28th Feb 20137:00 amPRNTotal Voting Rights
21st Feb 20132:35 pmPRNHolding(s) in Company
18th Feb 20132:53 pmPRNResult of General Meeting
31st Jan 201310:54 amPRNPlacing and Equity Finance Facility
24th Jan 20132:09 pmPRNNotice of Interest
18th Jan 201310:18 amPRNHolding(s) in Company
4th Jan 20132:59 pmPRNStatement Regarding Share Price Movement
12th Nov 201211:38 amPRNNotice of Interest
15th Oct 20122:01 pmPRNDirector Shareholding
12th Oct 20129:00 amPRNRPL554 Phase I/IIa data presented at ISAF 2012
26th Sep 20129:00 amPRNInvestor Presentation
17th Sep 201210:44 amPRNNew Option Scheme and Grant of Options
14th Sep 20127:00 amPRNHalf-yearly Report
6th Sep 20127:00 amPRNNotice of Interim Results
4th Sep 20127:30 amPRNVerona Pharma: RPL554 COPD Data Presented at ERS
3rd Sep 20129:30 amPRNNotice of Interest
28th Aug 20127:00 amPRNUS Patent Granted for Verona Pharma's RPL554
9th Jul 20127:00 amPRNVerona Pharma Investigates Anti-inflammatory - RPL554
1st Jun 20126:14 pmPRNResult of AGM
1st Jun 201211:30 amPRNCEO's Statement to Annual General Meeting
8th May 20124:56 pmPRNPosting of Annual Report
1st May 20127:00 amPRNVerona Pharma appoints new CEO
5th Apr 20127:00 amPRNVerona Pharma - Preliminary Unaudited Results
9th Mar 20127:00 amPRNVerona Pharma â€" First UK RPL554 anti-inflammatory trial
31st Jan 20127:00 amPRNTotal Voting Rights
16th Jan 201212:19 pmPRNNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.